利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

137 条记录 (耗时 0.039 秒)

    Polycyclic dithiophenes
    111.
    发明授权
    Polycyclic dithiophenes 有权
    多环二噻吩

    公开(公告)号：US09233930B2

    公开(公告)日：2016-01-12

    申请号：US13322506

    申请日：2010-05-21

    申请人： Hans Jürg Kirner ,  Natalia Chebotareva ,  Olivier Frédéric Aebischer

    发明人： Hans Jürg Kirner ,  Natalia Chebotareva ,  Olivier Frédéric Aebischer

    IPC分类号： C08G75/00 ,  C07D233/28 ,  C08G61/12 ,  H01L51/00 ,  H01L51/05

    CPC分类号： H01L51/0094 ,  C07D233/28 ,  C07D495/04 ,  C07D513/14 ,  C07F7/0814 ,  C08F128/06 ,  C08G61/122 ,  C08G61/123 ,  C08G61/126 ,  C08G75/06 ,  C08G75/32 ,  C08G2261/3241 ,  C08G2261/3243 ,  C08G2261/3247 ,  C08G2261/414 ,  C08G2261/92 ,  C09B57/00 ,  H01L51/0003 ,  H01L51/0036 ,  H01L51/0043 ,  H01L51/0071 ,  H01L51/0074 ,  H01L51/0545 ,  H01L51/0558 ,  Y02E10/549

    摘要： The present invention relates to novel compounds of the formula (I) wherein R1 and R1′ independently of each other are H or a substituent, halogen or SiR6R4R5; R2 and R2′ may be the same or different and are selected from C1-C25alkyl, C3-C12-cycloalkyl, C2-C25alkenyl, C2-C25alkynyl, C4-C25aryl, C5-C25alkylaryl or C5-C25aralkyl, each of which is unsubstituted or substituted, and under conditions as defined in claim 1, R2 and/or R2′ may also be halogen or hydrogen; X is a divalent linking group selected from formula (Ia) and formula (Ib); Y and Y′ independently are selected from formula (Ic), formula (Id), formula (Ie), formula (If), formula (Ig); n and p independently range from 0 to 6; where further symbols are as defined in claim 1, and to corresponding oligomers and (co)polymers. The compounds according to the invention are useful as semiconductors and have excellent solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.

    摘要翻译： 本发明涉及式（I）的新化合物，其中R1和R1'彼此独立地为H或取代基，卤素或SiR6R4R5; R2和R2'可以相同或不同，并且选自C 1 -C 25烷基，C 3 -C 12 - 环烷基，C 2 -C 25烯基，C 2 -C 25炔基，C 4 -C 25芳基，​​C 5 -C 25烷基芳基或C 5 -C 25芳烷基，其各自为未取代的或 并且在如权利要求1所定义的条件下，R 2和/或R 2'也可以是卤素或氢; X是选自式（Ia）和式（Ib）的二价连接基团; Y和Y'独立地选自式（Ic），式（Id），式（Ie），式（If），式（Ig）; n和p独立地为0至6; 其中符号如权利要求1中所定义，以及相应的低聚物和（共）聚合物。 根据本发明的化合物可用作半导体并且在有机溶剂中具有优异的溶解性和优异的成膜性能。 此外，当根据本发明的聚合物用于有机场效应晶体管，有机光伏（太阳能电池）中时，可以观察到高效率的能量转换，优异的场效应迁移率，良好的开/关电流比和/或优异的稳定性 ）和光电二极管。

    Substituted Imidazoline Compounds
    113.
    发明申请
    Substituted Imidazoline Compounds 审中-公开

    公开(公告)号：US20130338372A1

    公开(公告)日：2013-12-19

    申请号：US13533606

    申请日：2012-06-26

    申请人： Jetze Tepe ,  James Hamby

    发明人： Jetze Tepe ,  James Hamby

    IPC分类号： C07D233/28

    CPC分类号： C07D233/28

    摘要： The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB.

    Enantioselective transformation of α,β-unsaturated ketones using chiral organic catalysts
    116.
    发明授权
    Enantioselective transformation of α,β-unsaturated ketones using chiral organic catalysts 有权
    使用手性有机催化剂对α，β-不饱和酮的对映选择性转化

    公开(公告)号：US07592463B2

    公开(公告)日：2009-09-22

    申请号：US10313744

    申请日：2002-12-05

    申请人： David W. C. MacMillan ,  Alan B. Northrup

    发明人： David W. C. MacMillan ,  Alan B. Northrup

    IPC分类号： C07D233/28 ,  C07D235/02 ,  C07C45/69

    CPC分类号： C07D405/04 ,  B01J31/0237 ,  B01J31/0247 ,  B01J2231/326 ,  C07B2200/07 ,  C07C45/69 ,  C07C49/543 ,  C07C49/553 ,  C07C49/557 ,  C07C49/577 ,  C07C49/643 ,  C07C269/06 ,  C07D233/32 ,  C07C271/24

    摘要： Nonmetallic organic catalysts are provided that facilitate the enantioselective reaction of α,β-unsaturated ketones. The catalysts are chiral imidazolidinone compounds having the structure of formula (IIA) or (IIB) or are acid addition salts thereof, wherein, in one preferred embodiment, R1 is C1-C6 alkyl, R2 is phenyl or 2-methylfuryl, R3 and R4 are hydrogen, and R5 is phenyl optionally substituted with 1 or 2 substituents selected from the group consisting of halo, hydroxyl, and C1-C6 alkyl. The chiral imidazolidinones are useful in catalyzing a wide variety of reactions, including cycloaddition reactions, Friedel-Crafts alkylation reactions, and Michael additions.

    摘要翻译： 提供了促进α，β-不饱和酮的对映选择性反应的非金属有机催化剂。 催化剂是具有式（IIA）或（IIB）结构的手性咪唑烷酮化合物或其酸加成盐，其中在一个优选的实施方案中，R 1是C 1 -C 6烷基，R 2是苯基或2-甲基呋喃基，R 3和R 4 是氢，R5是任选被1或2个选自卤素，羟基和C 1 -C 6烷基的取代基取代的苯基。 手性咪唑烷酮可用于催化多种反应，包括环加成反应，Friedel-Crafts烷基化反应和迈克尔加成。

    Material for Electrolytic Solution, Ionic Material-Containing Composition and Use Thereof
    117.
    发明申请
    Material for Electrolytic Solution, Ionic Material-Containing Composition and Use Thereof 审中-公开
    电解液材料，含离子材料的组合物及其用途

    公开(公告)号：US20080138704A1

    公开(公告)日：2008-06-12

    申请号：US11596460

    申请日：2005-05-09

    申请人： Keiichiro Mizuta ,  Keiko Takebe

    发明人： Keiichiro Mizuta ,  Keiko Takebe

    IPC分类号： H01M10/40 ,  H01G9/035 ,  C07D207/16 ,  C07D233/28

    CPC分类号： H01G9/035 ,  H01G9/038 ,  H01G11/06 ,  H01G11/62 ,  H01M10/052 ,  H01M10/0567 ,  H01M10/0568 ,  H01M10/0569 ,  H01M2300/002 ,  H01M2300/0025 ,  Y02E60/13

    摘要： An object of the present invention is to provide a material for an electrolytic solution having improved ionic conductivity and, showing excellent in low temperature property, being stable with time, and being electrochemically stable at a high potential, and an ionic material-containing composition exhibiting excellent fundamental performance such as electrochemical stability, and preferably used in a variety of utilities. Another object of the present invention is to provide utilities thereof.The material for an electrolytic solution is the material containing an ionic compound, and the material comprises a cyano group-containing anion represented by the formula (1); and 1 to 99% by mass of a solvent in 100% by mass of the material for an electrolytic solution.

    摘要翻译： 本发明的目的是提供一种具有改进的离子导电性并且显示出优异的低温性能，随时间稳定且在高电位下电化学稳定的电解液的材料，以及含离子材料的组合物， 优异的基础性能，如电化学稳定性，优选用于各种用途。 本发明的另一个目的是提供其用途。 电解液的材料是含有离子性化合物的材料，该材料含有式（1）所示的含氰基的阴离子。 和100质量％的电解质材料中的1〜99质量％的溶剂。

    Substituted imidazoles as cannabinoid receptor modulators
    119.
    发明授权
    Substituted imidazoles as cannabinoid receptor modulators 失效

    公开(公告)号：US07057051B2

    公开(公告)日：2006-06-06

    申请号：US10198442

    申请日：2002-07-17

    申请人： Paul E. Finke ,  Sander G. Mills ,  Christopher W. Plummer ,  Shrenik K. Shah ,  Quang T. Truong

    发明人： Paul E. Finke ,  Sander G. Mills ,  Christopher W. Plummer ,  Shrenik K. Shah ,  Quang T. Truong

    IPC分类号： C07D233/28

    CPC分类号： C07D405/12 ,  C07D233/90

    摘要： The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.